At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 71 enrolled
Drug / intervention
CMK389 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Subject and Investigator Blinded, Placebo-controlled Multicenter Study to Assess the Efficacy and Safety of CMK389 in Patients With Moderate to Severe Atopic Dermatitis
In Brief
A Phase 2 clinical trial evaluating CMK389 and Placebo for Atopic Dermatitis. Completed, enrolled 71 participants across 18 sites in 6 countries.
Detailed Summary
The main purpose of this phase 2 study was to assess the efficacy and safety of CMK389 in patients with atopic dermatitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesCzechia, France, Germany, Hungary, Poland, Spain
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedApr 2021
Enrollment StartApr 2021
Primary CompletionJul 2022
Study CompletionDec 2022
TodayJul 2026
First PostedApr 8, 2021
Enrollment StartApr 20, 2021
Primary CompletionJul 14, 2022
Study CompletionDec 13, 2022
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 5.2 years ago
Interventions
CMK389biological
Active
Placebobiological
Placebo Comparator